Phibro Animal Health (NASDAQ:PAHC) CEO Sells $361,856.00 in Stock

February 19, 2026 by InsiderTrades.com

Key Points

Phibro CEO Jack Bendheim sold shares on Feb. 18 (7,040 shares for $361,856) as part of a concentrated selling spree from Jan. 22–Feb. 18 that totaled 238,158 shares for roughly $11.5 million, reducing his stake by 16.1% to 36,680 shares (≈$1.89M).
Phibro recently reported a quarterly beat (EPS $0.87 vs. $0.69 est.; revenue $373.9M vs. $355.6M), set FY2026 guidance of 2.93–3.10 EPS, and declared a $0.12 quarterly dividend (annual $0.48, ~0.9% yield).

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 7,040 shares of the company's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $51.40, for a total transaction of $361,856.00. Following the sale, the chief executive officer owned 36,680 shares of the company's stock, valued at $1,885,352. This represents a 16.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jack Bendheim also recently made the following trade(s):

On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.96, for a total transaction of $365,798.40.
On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.62, for a total value of $732,178.08.
On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.81, for a total value of $3,005,705.34.
On Thursday, February 5th, Jack Bendheim sold 110,842 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.38, for a total transaction of $5,362,535.96.
On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.15, for a total transaction of $144,848.00.
On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.47, for a total value of $400,600.20.
On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total transaction of $268,322.37.
On Thursday, January 29th, Jack Bendheim sold 6,772 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.12, for a total transaction of $271,692.64.
On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.55, for a total transaction of $50,079.25.
On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.98, for a total transaction of $552,372.84.

Phibro Animal Health Price Performance

PAHC stock opened at $51.08 on Thursday. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05. The firm has a 50 day moving average price of $41.97 and a 200-day moving average price of $39.69. Phibro Animal Health Corporation has a 52-week low of $16.16 and a 52-week high of $56.30. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of 22.70, a PEG ratio of 0.80 and a beta of 0.80.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The company had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Equities research analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th will be paid a $0.12 dividend. The ex-dividend date is Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a yield of 0.9%. Phibro Animal Health's payout ratio is presently 21.33%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Morgan Stanley set a $49.00 price target on shares of Phibro Animal Health in a research report on Friday, February 6th. JPMorgan Chase & Co. raised their price objective on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an "overweight" rating in a report on Friday, November 7th. Weiss Ratings restated a "buy (b-)" rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Finally, Zacks Research cut shares of Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Monday, February 9th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $37.50.

Read Our Latest Stock Analysis on PAHC

Hedge Funds Weigh In On Phibro Animal Health

Institutional investors and hedge funds have recently modified their holdings of the stock. 1620 Investment Advisors Inc. raised its stake in shares of Phibro Animal Health by 77.4% in the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company's stock valued at $25,000 after acquiring an additional 295 shares during the period. Farther Finance Advisors LLC raised its stake in shares of Phibro Animal Health by 113.2% during the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company's stock valued at $27,000 after acquiring an additional 386 shares in the last quarter. Hughes Financial Services LLC purchased a new stake in shares of Phibro Animal Health in the 3rd quarter worth $40,000. Rothschild Investment LLC increased its position in Phibro Animal Health by 2,500.0% during the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company's stock valued at $39,000 after purchasing an additional 1,000 shares during the period. Finally, iSAM Funds UK Ltd bought a new position in Phibro Animal Health in the third quarter worth approximately $61,000. Hedge funds and other institutional investors own 99.34% of the company's stock.

Phibro Animal Health Company Profile

(Get Free Report)

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.